The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 30, 2016

Filed:

Dec. 01, 2014
Applicant:

Her Majesty the Queen IN Right of Canada As Represented BY the Minister of Health, Winnipeg, CA;

Inventors:

Xuguang Li, Winnipeg, CA;

Runtao He, Winnipeg, CA;

Gary Van Domselaar, Winnipeg, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/40 (2006.01); A61K 45/06 (2006.01); A61K 39/145 (2006.01); C07K 16/10 (2006.01); G01N 33/569 (2006.01); G01N 33/573 (2006.01); C12N 9/24 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); A61K 39/12 (2013.01); C07K 16/1018 (2013.01); C07K 16/40 (2013.01); C12N 9/2402 (2013.01); C12Y 302/01018 (2013.01); G01N 33/56983 (2013.01); G01N 33/573 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/6081 (2013.01); C07K 2317/34 (2013.01); C12N 2760/16134 (2013.01); G01N 2333/9506 (2013.01);
Abstract

Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.


Find Patent Forward Citations

Loading…